Ergomed plc (2EM)의 가격은 얼마입니까?

Ergomed plc (2EM)의 가격은 $13.05입니다.

Ergomed plc (2EM)의 시가 총액은 무엇입니까?

Ergomed plc (2EM)의 시가 총액은 $695.07M입니다.

Ergomed plc (2EM) 수익

Ergomed plc, alongside its affiliated entities, offers a comprehensive range of clinical trial services, encompassing planning, oversight, and execution, in addition to providing essential drug safety and medical information support. The company maintains an expansive global footprint, conducting operations throughout the United Kingdom, continental Europe, the Middle East, Africa, North America, Asia, and Australia. Its business is organized into two core divisions: Clinical Research Services and Pharmacovigilance. Ergomed assists pharmaceutical, biotechnology, and generic drug manufacturers by managing clinical development programs, facilitating post-market approval strategies, and delivering robust pharmacovigilance solutions. Their expertise is concentrated in several therapeutic domains, including oncology, haematology, allergy, respiratory, and neurology/CNS, with a notable specialization in the development of orphan drugs. Furthermore, they extend support services to clinical trial sites. Established in 1997, the organization originally traded as Ergomed Clinical Research Limited before rebranding as Ergomed plc in June 2014. Its corporate headquarters are situated in Guildford, United Kingdom.

연도	매출	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

매출

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	매출	매출 차이	국가
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
CSL Limited CSL.AX	$15.74B	-	AU
Moderna, Inc. MRNA.US	$2.23B	-	US
Lonza Group AG LONN.SW	-	-	CH

회사

매출

매출 차이

국가

Vertex Pharmaceuticals Incorporated

VRTX.US

$12.62B

Argenx SE

ARGX.US

$6.02B

CSL Limited

CSL.AX

$15.74B

Moderna, Inc.

MRNA.US

$2.23B

Lonza Group AG

LONN.SW

Ergomed plc

2EM

카테고리